心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2020年急性心肌梗死质量指标的更新：急性心血管护理协会的立场文件：ACVC和NSTE-ACS指南组的质量指标研究组

2021-02-02 欧洲心脏病学会 Eur Heart J Acute Cardiovasc Care . 2021 Feb 7;zuaa037

心肌梗死

目的：质量指标（QIs）是改善循证医学交付的工具。 2017年，欧洲心脏病学会（ESC）急性心血管护理协会（ACVC）制定了一套急性心肌梗死（AMI）QI，已在国家和国际水平以及不同人群中进行了评估。

中文标题：

2020年急性心肌梗死质量指标的更新：急性心血管护理协会的立场文件：ACVC和NSTE-ACS指南组的质量指标研究组

英文标题：

2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group

发布机构：

欧洲心脏病学会

发布日期：

2021-02-02

简要介绍：

目的：质量指标（QIs）是改善循证医学交付的工具。 2017年，欧洲心脏病学会（ESC）急性心血管护理协会（ACVC）制定了一套急性心肌梗死（AMI）QI，已在国家和国际水平以及不同人群中进行了评估。但是，根据积累的经验和支持证据的变化，需要更新这些QI。

方法和结果：用于QI开发的ESC方法用于更新2017 ACVC QI。我们确定了AMI护理的关键领域，进行了文献综述，开发了候选QI列表，并使用改进的Delphi方法选择了最终指标集。此研究保留了2017年研究小组确定的AMI护理的相同七个领域。对于每个领域，主要和次要QIs分别反映了护理的基本和互补方面。总体而言，本文档中提出了26个QI，而2017年为20个。本文档中提出了新的QI（例如，高敏感性肌钙蛋白的中心使用），其中一些保留或被修改（例如，医院内风险评估），而另一些则根据证据的变化而退出[例如： fondaparinux治疗的非ST段抬高型心肌梗死（NSTEMI）患者的比例]和可行性评估（例如，使用GRACE和CRUSADE风险评分进行风险评估的NSTEMI患者的比例）。

结论：根据当代知识和积累的经验，开发了用于AMI管理的更新QI。这些QI可用于评估和改善AMI护理的质量。

相关资料下载：
[AttachmentFileName(sort=1, fileName=zuaa037.pdf)] GetToolGuiderByIdResponse(projectId=1, id=f9fab1c0020539d5, title=2020年急性心肌梗死质量指标的更新：急性心血管护理协会的立场文件：ACVC和NSTE-ACS指南组的质量指标研究组 , enTitle=2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group, guiderFrom=Eur Heart J Acute Cardiovasc Care . 2021 Feb 7;zuaa037, authorId=0, author=, summary=目的：质量指标（QIs）是改善循证医学交付的工具。 2017年，欧洲心脏病学会（ESC）急性心血管护理协会（ACVC）制定了一套急性心肌梗死（AMI）QI，已在国家和国际水平以及不同人群中进行了评估。, cover=, journalId=0, articlesId=null, associationId=62, associationName=欧洲心脏病学会, associationIntro=是目前在欧洲居于首要地位的心脏病学会，会员超过70000人、提供更新指南、调查数据、组织学术会议，ESC年会是心血管领域最大的会议。下设5个分会（超声心动图学会、心律学会、心衰学会、预防与康复学会及介入学会）。提供指南较全面，按年份排列。现提供有手机板本。, copyright=0, guiderPublishedTime=Tue Feb 02 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span class="VIiyi" lang="zh-CN"><span class="JLqJ4b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="0">目的：质量指标（QIs）是改善循证医学交付的工具。 2017年，欧洲心脏病学会（ESC）急性心血管护理协会（ACVC）制定了一套急性心肌梗死（AMI）QI，已在国家和国际水平以及不同人群中进行了评估。但是，根据积累的经验和支持证据的变化，需要更新这些QI。 </span></span></p> <p><span class="VIiyi" lang="zh-CN"><span class="JLqJ4b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="0">方法和结果：用于QI开发的ESC方法用于更新2017 ACVC QI。我们确定了AMI护理的关键领域，进行了文献综述，开发了候选QI列表，并使用改进的Delphi方法选择了最终指标集。此研究保留了2017年研究小组确定的AMI护理的相同七个领域。对于每个领域，主要和次要QIs分别反映了护理的基本和互补方面。总体而言，本文档中提出了26个QI，而2017年为20个。本文档中提出了新的QI（例如，高敏感性肌钙蛋白的中心使用），其中一些保留或被修改（例如，医院内风险评估），而另一些则根据证据的变化而退出[例如： fondaparinux治疗的非ST段抬高型心肌梗死（NSTEMI）患者的比例]和可行性评估（例如，使用GRACE和CRUSADE风险评分进行风险评估的NSTEMI患者的比例）。 </span></span></p> <p><span class="VIiyi" lang="zh-CN"><span class="JLqJ4b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="0">结论：根据当代知识和积累的经验，开发了用于AMI管理的更新QI。这些QI可用于评估和改善AMI护理的质量。</span></span></p>, tagList=[TagDto(tagId=334, tagName=心肌梗死)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3126, appHits=241, showAppHits=0, pcHits=790, showPcHits=2885, likes=1, shares=11, comments=7, approvalStatus=1, publishedTime=Wed Feb 10 19:55:57 CST 2021, publishedTimeString=2021-02-02, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Wed Feb 10 19:43:23 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 21:46:51 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=zuaa037.pdf)])
zuaa037.pdf
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1070241, encodeId=e21710e0241fd, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7405709491, createdName=ms3000002046126282, createdTime=Sun Nov 14 21:27:18 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055945, encodeId=dda3105594519, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Wed Sep 29 08:57:21 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006396, encodeId=07381006396f7, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd751668378, createdName=1de060e9m63(暂无匿称), createdTime=Mon Aug 09 18:35:21 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002710, encodeId=3fae1002e1022, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8fd5556812, createdName=ms1000000697198106, createdTime=Mon Jul 26 11:49:57 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963105, encodeId=5bbd96310552, content=贴近临床，有指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c941610067, createdName=24125220, createdTime=Thu May 06 14:53:59 CST 2021, time=2021-05-06, status=1, ipAttribution=)]
    2021-11-14 ms3000002046126282

    很实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1070241, encodeId=e21710e0241fd, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7405709491, createdName=ms3000002046126282, createdTime=Sun Nov 14 21:27:18 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055945, encodeId=dda3105594519, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Wed Sep 29 08:57:21 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006396, encodeId=07381006396f7, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd751668378, createdName=1de060e9m63(暂无匿称), createdTime=Mon Aug 09 18:35:21 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002710, encodeId=3fae1002e1022, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8fd5556812, createdName=ms1000000697198106, createdTime=Mon Jul 26 11:49:57 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963105, encodeId=5bbd96310552, content=贴近临床，有指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c941610067, createdName=24125220, createdTime=Thu May 06 14:53:59 CST 2021, time=2021-05-06, status=1, ipAttribution=)]
    2021-09-29 H8888888

    感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1070241, encodeId=e21710e0241fd, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7405709491, createdName=ms3000002046126282, createdTime=Sun Nov 14 21:27:18 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055945, encodeId=dda3105594519, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Wed Sep 29 08:57:21 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006396, encodeId=07381006396f7, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd751668378, createdName=1de060e9m63(暂无匿称), createdTime=Mon Aug 09 18:35:21 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002710, encodeId=3fae1002e1022, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8fd5556812, createdName=ms1000000697198106, createdTime=Mon Jul 26 11:49:57 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963105, encodeId=5bbd96310552, content=贴近临床，有指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c941610067, createdName=24125220, createdTime=Thu May 06 14:53:59 CST 2021, time=2021-05-06, status=1, ipAttribution=)]
    2021-08-09 1de060e9m63(暂无匿称)

    实用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1070241, encodeId=e21710e0241fd, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7405709491, createdName=ms3000002046126282, createdTime=Sun Nov 14 21:27:18 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055945, encodeId=dda3105594519, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Wed Sep 29 08:57:21 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006396, encodeId=07381006396f7, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd751668378, createdName=1de060e9m63(暂无匿称), createdTime=Mon Aug 09 18:35:21 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002710, encodeId=3fae1002e1022, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8fd5556812, createdName=ms1000000697198106, createdTime=Mon Jul 26 11:49:57 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963105, encodeId=5bbd96310552, content=贴近临床，有指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c941610067, createdName=24125220, createdTime=Thu May 06 14:53:59 CST 2021, time=2021-05-06, status=1, ipAttribution=)]
    2021-07-26 ms1000000697198106

    感谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1070241, encodeId=e21710e0241fd, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7405709491, createdName=ms3000002046126282, createdTime=Sun Nov 14 21:27:18 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055945, encodeId=dda3105594519, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Wed Sep 29 08:57:21 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1006396, encodeId=07381006396f7, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd751668378, createdName=1de060e9m63(暂无匿称), createdTime=Mon Aug 09 18:35:21 CST 2021, time=2021-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002710, encodeId=3fae1002e1022, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8fd5556812, createdName=ms1000000697198106, createdTime=Mon Jul 26 11:49:57 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=963105, encodeId=5bbd96310552, content=贴近临床，有指导意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c941610067, createdName=24125220, createdTime=Thu May 06 14:53:59 CST 2021, time=2021-05-06, status=1, ipAttribution=)]
    2021-05-06 24125220

    贴近临床，有指导意义

    0

相关指南

心肌细胞死亡评估指南【用于体外实验】

暂未更新 · 2020-02-01

2019 AHA科学声明：无阻塞性冠状动脉疾病心肌梗死患者的诊断和管理

美国心脏协会(AHA,American Heart Association) · 2019-03-27

第四次心肌梗死全球统一定义(2018)要点解读：重视心肌损伤，细化心肌梗死诊断

暂未更新 · 2018-11-30

2018 第四版心肌梗死通用定义

美国心脏病学会(ACC,American College of Cardiology) · 2018-08-25

“情人节”别伤心：关于心脏的靠谱指南

暂未更新 · 2017-02-13

2016 急性ST段抬高型心肌梗死溶栓治疗的合理用药指南

中国药师协会 · 2016-08-30